Advertisement

Breast Cancer Research and Treatment

, Volume 158, Issue 2, pp 203–217 | Cite as

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

  • K. A. Nyrop
  • G. R. Williams
  • H. B. Muss
  • S. S. Shachar
Review

Abstract

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9–17 %), stable weight (47–64 %), and gained weight (27–36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.

Keywords

Breast cancer Weight gain Endocrine treatment 

Notes

Funding

This work was supported by funding from the University Cancer Research Fund of the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Dixon JK, Moritz DA, Baker FL (1978) Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum 5(3):5–7PubMedGoogle Scholar
  2. 2.
    Knobf MK, Mullen JC, Xistris D, Moritz DA (1983) Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 10(2):28–33PubMedGoogle Scholar
  3. 3.
    Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd NF (1985) Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5(2):195–200PubMedCrossRefGoogle Scholar
  4. 4.
    Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294PubMedCrossRefGoogle Scholar
  5. 5.
    Fedele P, Orlando L, Schiavone P et al (2014) BMI variation increases recurrence risk in women with early-stage breast cancer. Future Oncol 10(15):2459–2468PubMedCrossRefGoogle Scholar
  6. 6.
    Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24(10):2506–2514PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Nechuta S, Chen WY, Cai H et al (2016) A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138(9):2088–2097PubMedCrossRefGoogle Scholar
  8. 8.
    Sinicrope FA, Dannenberg AJ (2011) Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 29(1):4–7PubMedCrossRefGoogle Scholar
  9. 9.
    Bradshaw PT, Ibrahim JG, Stevens J, Cleveland RJ, Abrahamson PE et al (2012) Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23(2):320–327PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635PubMedCrossRefGoogle Scholar
  12. 12.
    Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML (2015) Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 107(12):djv275PubMedCrossRefGoogle Scholar
  13. 13.
    Caan BJ, Emond JA, Su HI et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 30(13):1492–1497PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Young A, Weltzien E, Kwan M, Castillo A, Caan B, Kroenke CH (2014) Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors. J Cancer Surviv 8(4):539–547PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Forsythe LP, Alfano CM, George SM et al (2013) Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior. Breast Cancer Res Treat 137(2):617–630PubMedCrossRefGoogle Scholar
  16. 16.
    Befort CA, Austin H, Klemp JR (2011) Weight control needs and experiences among rural breast cancer survivors. Psychooncology 20(10):1069–1075PubMedCrossRefGoogle Scholar
  17. 17.
    Voskuil DW, van Nes JG, Junggeburt JM, van de Velde CJ, van Leeuwen FE, de Haes JC (2010) Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann Oncol 21(10):2094–2101PubMedCrossRefGoogle Scholar
  18. 18.
    Schmitz KH, Neuhouser ML, Agurs-Collins T et al (2013) Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst 105(18):1344–1354PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Keegan TH, Kurian AW, Gali K et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105(5):938–946PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Kroenke CH, Michael YL, Shu XO, Poole EM (2016) Post-diagnosis social networks, and lifestyle and treatment factors in the After Breast Cancer Pooling Project. Psychooncology. doi: 10.1002/pon.4059 PubMedGoogle Scholar
  21. 21.
    Makari-Judson G, Braun B, Jerry DJ, Mertens WC (2014) Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Onc. 5(3):272–282CrossRefGoogle Scholar
  22. 22.
    Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–518Google Scholar
  23. 23.
    Surveillance Epidemiology and End Results (SEER) (2016) Breast cancer: SEER fact sheets. National Cancer Institute. 2016. http://seer.cancer.gov/statfacts/html/breast/html. Accessed 02 Aug 2016
  24. 24.
    Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1899–1905PubMedCrossRefGoogle Scholar
  25. 25.
    Benz CC (2008) Impact of aging on the biology of breast cancer. Crit Rev Oncog Hematol 66(1):65–74CrossRefGoogle Scholar
  26. 26.
    Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ et al (2015) Breast cancer, version 1.2016. J Natl Compr Canc Netw 13(12):1475–1485PubMedGoogle Scholar
  27. 27.
    Taylor WC, Muss HB (2010) Recent advances: adjuvant therapy for older women with breast cancer. Cancer J 16(4):289–293PubMedCrossRefGoogle Scholar
  28. 28.
    Eisen A, Fletcher GG, Gandhi S et al (2015) Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 22(Suppl 1):S67–S81PubMedPubMedCentralGoogle Scholar
  29. 29.
    Burstein HJ, Griggs JJ, Prestrud AA, Temin S (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 6(5):243–246Google Scholar
  30. 30.
    Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271PubMedCrossRefGoogle Scholar
  31. 31.
    Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134(2):727–734PubMedCrossRefGoogle Scholar
  33. 33.
    Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917PubMedCrossRefGoogle Scholar
  34. 34.
    Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedCrossRefGoogle Scholar
  35. 35.
    Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940PubMedCrossRefGoogle Scholar
  37. 37.
    van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331PubMedCrossRefGoogle Scholar
  38. 38.
    Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19(10):1319–1328PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. 132(2):1107–1118Google Scholar
  40. 40.
    Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ (2012) Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climacteric 15(4):339–349PubMedCrossRefGoogle Scholar
  41. 41.
    Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Zivian MT, Salgado B (2008) Side effects revisited: women’s experiences with aromatase inhibitors. Breast Cancer Action, San FranciscoGoogle Scholar
  43. 43.
    Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B et al (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128(2):553–561PubMedCrossRefGoogle Scholar
  44. 44.
    Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498PubMedCrossRefGoogle Scholar
  45. 45.
    Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57CrossRefGoogle Scholar
  46. 46.
    Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast. 13(5):363–368PubMedCrossRefGoogle Scholar
  47. 47.
    Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K (2015) Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer. Cancer Epi Biomarkers Prev 24(8):1262–1269CrossRefGoogle Scholar
  48. 48.
    Mortimer J, Behrendt CE (2013) Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis. J Palliat Med 16(9):1130–1134PubMedCrossRefGoogle Scholar
  49. 49.
    Sedjo RL, Hines LM, Byers T et al (2013) Long-term weight gain among Hispanic and non-Hispanic White women with and without breast cancer. Nutr Cancer 65(1):34–42PubMedCrossRefGoogle Scholar
  50. 50.
    Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer–effect of tamoxifen. Breast Cancer Res Treat 22(2):129–132PubMedCrossRefGoogle Scholar
  51. 51.
    Gu K, Chen X, Zheng Y et al (2010) Weight change patterns among breast cancer survivors: results from the Shanghai breast cancer survival study. Cancer Causes Control 21(4):621–629PubMedCrossRefGoogle Scholar
  52. 52.
    Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the Women’s healthy Eating and Living (WHEL) study. Breast Cancer Res Treat 105(2):177–186PubMedCrossRefGoogle Scholar
  53. 53.
    Francini G, Petrioli R, Montagnani A et al (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95(2):153–158PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Sedjo R, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. Cancer Surv 8(3):410–418CrossRefGoogle Scholar
  55. 55.
    Reddy S, Sadim M, Li J et al (2013) Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Br J Cancer 109(4):872–881PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Han HS, Lee KW, Kim JH et al (2009) Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat 114(1):147–153PubMedCrossRefGoogle Scholar
  57. 57.
    Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129PubMedGoogle Scholar
  58. 58.
    Makari-Judson G, Judson CH, Mertens WC (2007) Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. Breast 13(3):258–265CrossRefGoogle Scholar
  59. 59.
    Chen X, Lu W, Gu K et al (2011) Weight change and its correlates among breast cancer survivors. Nutr Cancer 63(4):538–548PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Irwin ML, McTiernan A, Baumgartner RN, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Kumar NB, Allen K, Cantor A et al (1997) Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat 44(2):135–143PubMedCrossRefGoogle Scholar
  62. 62.
    Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 13(5):363–368PubMedCrossRefGoogle Scholar
  63. 63.
    Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedCrossRefGoogle Scholar
  64. 64.
    Su H, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57CrossRefGoogle Scholar
  66. 66.
    McGowan P, Perry M, Hewett J, Ge B, Sanfilippo K (2006) Weight gain in breast cancer patients: tamoxifen versus anastrozole. J Clin Oncol 24(18S (June 20 Suppl)):10544Google Scholar
  67. 67.
    Lin CJ, DeRoo LA, Jacobs SR, Sandler DP (2012) Accuracy and reliability of self-reported weight and height in the Sister Study. Public health Nutr 15(6):989–999PubMedCrossRefGoogle Scholar
  68. 68.
    Weaver TW, Kushi LH, McGovern PG et al (1996) Validation study of self-reported measures of fat distribution. Int J Obes Relat Metab Disord 20(7):644–650PubMedGoogle Scholar
  69. 69.
    Gillum RF, Sempos CT (2005) Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J 4:27PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Lim U, Wilkens LR, Albright CL, Novotny R, Le Marchand L, Kolonel LN (2013) University of Hawai’i Cancer Center Connection: bias in self-reported anthropometry in relation to adiposity and adulthood weight gain among postmenopausal Caucasian and Japanese American Women. Hawai’i J Med Public Health 72(12):445–449Google Scholar
  71. 71.
    Bradshaw PT, Nichols HB, Caan BJ (2016) RE: weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 108(4):djw023PubMedCrossRefGoogle Scholar
  72. 72.
    Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW (2009) The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45:119–126PubMedCrossRefGoogle Scholar
  74. 74.
    Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883PubMedCrossRefGoogle Scholar
  75. 75.
    Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CHG, van Laarhoven HWM (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer. Cancer Nurs 1–8Google Scholar
  76. 76.
    Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH (2014) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 20(1):22–28PubMedCrossRefGoogle Scholar
  77. 77.
    Kim SH, Cho YU, Kim SJ (2013) Weight gain and its correlates among breast cancer survivors. Asian Nurs Res 7(4):161–167CrossRefGoogle Scholar
  78. 78.
    DeSantis CE, Lin CC, Mariotto AB et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–257PubMedCrossRefGoogle Scholar
  79. 79.
    Colleoni M, Gelber S, Goldhirsch A et al (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13–93. J Clin Oncol 24(9):1332–1341PubMedCrossRefGoogle Scholar
  80. 80.
    Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917PubMedCrossRefGoogle Scholar
  81. 81.
    Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331PubMedCrossRefGoogle Scholar
  83. 83.
    Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10027):857–865PubMedCrossRefGoogle Scholar
  84. 84.
    Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107–1118PubMedCrossRefGoogle Scholar
  85. 85.
    Glaus A, Boehme C, Thürlimann B et al (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17(5):801–806PubMedCrossRefGoogle Scholar
  86. 86.
    McInnes J, Knobf MT (2001) Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nurs Forum 28(4):675–684PubMedGoogle Scholar
  87. 87.
    Love RR, Hutson PR, Havighurst TC, Cleary JF (2005) Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin Cancer Res 11(4):1500–1503PubMedCrossRefGoogle Scholar
  88. 88.
    Sedjo RL, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. J Cancer Surviv 8(3):410–418PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Basaran G, Turhal NS, Cabuk D et al (2011) Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol 28(2):409–415PubMedCrossRefGoogle Scholar
  90. 90.
    Vagenas D, DiSipio T, Battistutta D et al (2015) Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15(1):28 (Epub ahead of print) PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • K. A. Nyrop
    • 1
  • G. R. Williams
    • 1
  • H. B. Muss
    • 1
  • S. S. Shachar
    • 2
  1. 1.School of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.School of MedicineUniversity of North Carolina at Chapel HillHaifaIsrael

Personalised recommendations